Related Experiment Video
Updated: Jan 14, 2026

Author Spotlight: Advances in Evaluating Human Lung Epithelial Cells' Response to Metal-Organic Frameworks
Published on: May 26, 2023
Exploration of a framework to identify cohort of concern substances in medical device risk assessment
Mao-Wen Weng1, Xiaoling Sharlene Dai1, Shaoping Wu1
1Abbott Laboratories Medical Devices, St. Paul, Minnesota, USA.
Abstract:
Cohort of concern substances (CoCs) present challenges in medical device toxicological risk assessment. They are excluded from the lifetime threshold of toxicological concern (TTC) per ISO/TS 21726, because their toxic dose is < 1.5 μg/day and they may present a higher cancer risk. Relying solely on structural similarities with known toxicants is inadequate for assessing carcinogenic potency. This study selected chemicals from the Carcinogenic Potency Database (CPDB) to establish a framework for identifying potential CoCs. To do that, a threshold of Cancer Risk Specific Dose (CRSD) < 0.025 μg/kg/day was initially applied. Chemicals meeting this criterion are recognized as CoCs. However, the risk assessment could be impeded by particular uncertainties, such as the inability to determine the CRSD. In such cases, the identified CoCs were further categorized based on their mutagenicity determined by the Ames test results. A scatterplot reveals a significant correlation between the carcinogenic potency [ Log(0.5/TD50)+7] and acute systemic toxicity [Log(LD50)] in the CoCs-Ames (-) group (R2 = 0.72). For the CoCs-Ames (+) group (n = 124), 18 CoCs with available mutation slope data show cancer risk greater than the default risk of 1 in 100,000. This study provides a framework integrating scientific evidence and regulatory guidelines to identify potential CoCs.
More Related Videos
11:38High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
09:04Identifying Per- and Polyfluorinated Chemical Species with a Combined Targeted and Non-Targeted-Screening High-Resolution Mass Spectrometry Workflow
Published on: April 18, 2019
Related Concept Videos
Clinically Relevant Drug Product Specifications: Methods of Establishment
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Mutagenicity and Carcinogenicity
Drug Regulation
Therapeutic Drug Monitoring: Drug Analysis Methods